ERES East Resources Acquisition Company

Growing Private Pharmaceutical Organization Awards $1.1 Million Study to eResearchTechnology for Cardiac Safety Monitoring and Information Distribution Services Thorough Phase I ECG Study for Key Compound to Be Performed Over 90-Day Period PHILADELPHIA, April 26 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), , a leading provider of centralized electrocardiographic (ECG) collection and interpretation services, announced today that it has received an agreement for more than $1.1 million in cardiac safety monitoring and services from a growing private pharmaceutical organization for one of its drug candidates in clinical development. The agreement covers an extensive Phase I study for which eRT is providing comprehensive support including the provision, training and ongoing assistance required for effective use of digital 12-lead Holter equipment designed to facilitate 24-hour digital recording of cardiac safety data that is subsequently provided to eRT for analysis. eRT will perform digital collection, measurement, interpretation, review, and distribution of cardiac safety data through its EXPeRT workflow enabled data handling technology, the first solution in production that was designed explicitly to meet emerging international regulatory guidance and technical standards. The study is targeted for completion over a 90-day period. "We are pleased to have been selected to provide cardiac safety services for the first Thorough Phase I ECG Study conducted by this recently established and fast-growing organization," said Scott Grisanti, senior vice president of business development and chief marketing officer at eRT. "The combination of eRT's operational expertise in the demanding Thorough Phase I ECG Study arena and experience in the anti-infective therapeutic area targeted by this compound, position our company to make a valuable contribution to this drug developer's efforts." Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development. Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. The sponsor may cancel this agreement at its sole discretion. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company's financial results can be found in the company's Report on Form 10-K filed with the Securities and Exchange Commission. DATASOURCE: eResearchTechnology, Inc. CONTACT: Joan Sterlacci, eResearchTechnology, Inc., +1-908-203-6473; or Matt Hayden, Hayden Communications, +1-858-456-4533, for eResearchTechnology Web site: http://www.ert.com/

Copyright